Inhibrx Biosciences Investor Relations Material
Latest events
Q4 2024
16 Mar, 2025
Q4 2023
28 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Inhibrx Biosciences Inc
Access all reports
Inhibrx Biosciences Inc. is a clinical-stage biotechnology company focused on developing biologic therapeutic candidates. The company's work is centered on leveraging its proprietary protein engineering platforms to design and develop therapies aimed at treating serious and life-threatening conditions. Inhibrx's pipeline includes multiple candidates that target various pathways involved in cancer and other critical diseases, with several programs in clinical trials. Inhibrx Biosciences is headquartered in La Jolla, California, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
INBX
Country
🇺🇸 United States